Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial
Status:
Not yet recruiting
Trial end date:
2024-11-15
Target enrollment:
Participant gender:
Summary
AdAM is a prospective, randomized, controlled, double-blinded, monocentric trial in patients
receiving surgical therapy due to anal HPV infection.
Aim of the study is to evaluate efficacy of combination therapy (surgical therapy + topical
Imiquimod-therapy). It is planned to include 200 patients.
100 patients receive surgical therapy+ topical Imiquimod therapy, 100 patients receive
surgical therapy + topical Placebo therapy